SCA Pharma’s CEO Milton Boyer Addresses 8th Annual Global Healthcare Executive Summit

Windsor, CT - Milton Boyer, CEO of SCA Pharma, a nationally recognized FDA 503B outsourcing facility with locations in Little Rock, AK and Windsor, CT was honored to be a keynote speaker at the 8th Annual Global Healthcare Executive Summit presented by Bourne Partners which took place on October 2, 2018 in Charlotte, NC. The summit brought together executive leaders to discuss and speak on trending topics in the healthcare sector.

With over 25 years of experience in the pharmaceutical industry, the focus of Mr. Boyer’s discussion centered around the evolving demand for 503B compounding facilities in healthcare and the state in the evolving sterile compounding space.

With the 2013 Drug Quality and Security Act (DQSA) changing the scope of demand for outsourcing compound facilities by the FDA, Mr. Boyer states “Quality, commitment, and service should be the driving force for every 503B.”

With a focus on client relationship, Boyer emphasized “cGMP Quality standards, constant communication with clients, and transparency as the most important aspects of a successful 503B company. This model has been implemented in SCA’s mission to ensure client trust and patient safety.”

SCA has built trusted relationships with their customers delivering core cGMP policies and procedures, innovative technology for testing and manufacturing, and a robust training program for its employees that ensures quality and care of products for patients.

As the 503B space continues to evolve, SCA is poised and ready to meet the needs of an ever-changing industry. . Mr. Boyer concluded “The demand for reputable, high-quality 503B companies is on the rise, we see an opportunity to grow and meet the demands of medication shortages and compound medication with hospitals.

SCA is growing to meet those demands. In November 2017, SCA Pharma opened a 90,000ft2 production facility in Windsor, CT and is expanding their workforce in Q4 2018 adding a second production shift to meet the growing demand of their customers and the 503B industry as a whole.

About SCA Pharma

SCA Pharma is an FDA 503B outsourcing facility providing the highest quality sterile admixtures and prefilled syringes. Licensed in all 50 states, SCA offers a robust catalog, as well as outstanding quality and customer service. Since day 1, SCA has performed 100% final product sterility testing with lot-specific lab reports for every sterile product produced. SCA additionally performs environmental monitoring and full endotoxin testing on every batch of sterile products, prior to release, fulfilling requirements for Endotoxin (Pyrogen) testing per USP Guidelines and cGMP guidance.

For more information, visit

Media Contact

Brenden Roche


Shannon Daley